ES2878118T3 - Inhibidores de beta-lactamasa - Google Patents

Inhibidores de beta-lactamasa Download PDF

Info

Publication number
ES2878118T3
ES2878118T3 ES13861198T ES13861198T ES2878118T3 ES 2878118 T3 ES2878118 T3 ES 2878118T3 ES 13861198 T ES13861198 T ES 13861198T ES 13861198 T ES13861198 T ES 13861198T ES 2878118 T3 ES2878118 T3 ES 2878118T3
Authority
ES
Spain
Prior art keywords
optionally substituted
cr6r7
nr4r5
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13861198T
Other languages
English (en)
Spanish (es)
Inventor
Christopher Burns
Denis Daigle
Bin Liu
Daniel Mcgarry
Daniel C Pevear
Robert E Lee Trout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VenatoRx Pharmaceuticals Inc
Original Assignee
VenatoRx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VenatoRx Pharmaceuticals Inc filed Critical VenatoRx Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2878118T3 publication Critical patent/ES2878118T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
ES13861198T 2012-12-07 2013-12-05 Inhibidores de beta-lactamasa Active ES2878118T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734900P 2012-12-07 2012-12-07
US201361783238P 2013-03-14 2013-03-14
PCT/US2013/073428 WO2014089365A1 (en) 2012-12-07 2013-12-05 Beta-lactamase inhibitors

Publications (1)

Publication Number Publication Date
ES2878118T3 true ES2878118T3 (es) 2021-11-18

Family

ID=50884012

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13861198T Active ES2878118T3 (es) 2012-12-07 2013-12-05 Inhibidores de beta-lactamasa

Country Status (16)

Country Link
US (6) US9422314B2 (enExample)
EP (2) EP3922635A1 (enExample)
JP (2) JP6403219B2 (enExample)
KR (1) KR102147420B1 (enExample)
CN (1) CN105026407B (enExample)
AU (1) AU2013355110B2 (enExample)
BR (1) BR112015013123B1 (enExample)
CA (1) CA2893943C (enExample)
ES (1) ES2878118T3 (enExample)
HR (1) HRP20210879T1 (enExample)
IL (1) IL239212B (enExample)
PL (1) PL2928898T3 (enExample)
PT (1) PT2928898T (enExample)
RU (1) RU2654692C2 (enExample)
WO (1) WO2014089365A1 (enExample)
ZA (1) ZA201504200B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2603514B1 (en) 2010-08-10 2018-07-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
JP6403219B2 (ja) * 2012-12-07 2018-10-10 ベナトルクス ファーマシューティカルズ,インク. ベータ−ラクタマーゼ阻害剤
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP2016509594A (ja) * 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
AU2014204046B2 (en) 2013-01-04 2017-02-23 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
MX2016015093A (es) * 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
KR20220065084A (ko) * 2014-06-11 2022-05-19 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20150361108A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016100043A1 (en) * 2014-12-19 2016-06-23 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
US10336702B2 (en) 2014-12-23 2019-07-02 Bergenbio Asa Pharmaceutically active compounds
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017044828A1 (en) * 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) * 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
EP3478693B1 (en) * 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
GB201613946D0 (en) * 2016-08-15 2016-09-28 Univ Oslo Compounds
SG11201908181XA (en) * 2017-03-06 2019-10-30 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2018199291A1 (ja) * 2017-04-28 2018-11-01 大日本住友製薬株式会社 ヘテロ環誘導体
GB201708002D0 (en) 2017-05-18 2017-07-05 Univ Oxford Innovation Ltd ß-Lactamase inhibitors
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
JP7377545B2 (ja) 2017-10-11 2023-11-10 キューペックス バイオファーマ, インコーポレイテッド ボロン酸誘導体およびその合成
CN111556872B (zh) * 2017-11-01 2024-05-10 梅琳塔治疗公司 硼酸酯衍生物的合成及其用途
CA3097127A1 (en) 2018-04-20 2019-10-24 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2019208797A1 (ja) 2018-04-27 2019-10-31 大日本住友製薬株式会社 オキソ置換化合物
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN113015532B (zh) * 2018-09-12 2024-03-15 维纳拓尔斯制药公司 包含β-内酰胺酶抑制剂的组合式组合物
CA3135614A1 (en) * 2019-04-02 2020-10-08 VenatoRx Pharmaceuticals, Inc. Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof
JP7550421B2 (ja) * 2019-10-25 2024-09-13 住友ファーマ株式会社 オキソ置換化合物からなる医薬
JP7654554B2 (ja) 2019-10-25 2025-04-01 住友ファーマ株式会社 新規置換縮環型化合物
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
TW202128718A (zh) 2019-11-26 2021-08-01 美商維納拓爾斯製藥公司 青黴素結合蛋白抑制劑
US20240294554A1 (en) * 2020-08-20 2024-09-05 Phaeno Therapeutics Co., Ltd Boracic acid compound
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
US20250340577A1 (en) * 2021-03-02 2025-11-06 Case Western Reserve University Beta-lactomase inhibitors and uses thereof
BR112023017203A2 (pt) 2021-04-13 2023-11-07 Tuojie Biotech Shanghai Co Ltd Derivado de ácido bórico que age como inibidor de beta-lactamase
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技(杭州)有限公司 新的硼酸类化合物的晶型及其制备方法
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ177159A (en) 1974-04-20 1978-03-06 Beecham Group Ltd Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
IT1283467B1 (it) * 1996-07-19 1998-04-21 Menarini Farma Ind Derivati di cicloalcani 1,2 sostituiti come inibitori della trombina, procedimento per la loro preparazione e loro impiego in formulazioni
PT1212327E (pt) 1999-09-17 2004-01-30 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
AU2004256841A1 (en) 2003-06-10 2005-01-20 Fulcrum Pharmaceuticals, Inc. Beta-lactamase inhibitors and methods of use thereof
PL4008721T3 (pl) 2004-03-30 2024-05-13 Millennium Pharmaceuticals, Inc. Synteza związków estrów i kwasów boronowych
CN1965838A (zh) 2005-11-17 2007-05-23 李海超 含头孢匹胺和β-内酰胺酶抑制剂的药物组合物
CA2629570C (en) 2005-12-07 2012-11-27 Basilea Pharmaceutica Ag Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
EA201000774A1 (ru) 2007-11-13 2010-12-30 Новартис Интернэшнл Фармасьютикл Лтд. Ингибиторы бета-лактамазы
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
PL2231667T3 (pl) * 2008-01-18 2014-01-31 Merck Sharp & Dohme Inhibitory beta-laktamazy
AR076667A1 (es) 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
JP2013500974A (ja) 2009-07-28 2013-01-10 アナコール ファーマシューティカルズ,インコーポレイテッド 三置換ホウ素含有分子
EP2603514B1 (en) 2010-08-10 2018-07-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP2768503A1 (en) 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
SG11201400293UA (en) 2011-09-04 2014-08-28 Glytech Inc Glycosylated polypeptide and drug composition containing said polypeptide
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
SG10201605152SA (en) 2011-12-22 2016-08-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
JP6018319B2 (ja) 2012-12-03 2016-11-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 置換トリアゾールボロン酸化合物
JP6403219B2 (ja) * 2012-12-07 2018-10-10 ベナトルクス ファーマシューティカルズ,インク. ベータ−ラクタマーゼ阻害剤
JP2016509594A (ja) 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
AU2014204046B2 (en) 2013-01-04 2017-02-23 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
MX2016015093A (es) 2014-05-19 2017-03-27 Rempex Pharmaceuticals Inc Derivados de acido boronico y sus usos terapeuticos.
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
US20150361107A1 (en) * 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
KR20220065084A (ko) 2014-06-11 2022-05-19 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN106687116B (zh) 2014-09-04 2020-07-24 盐野义制药株式会社 含有具有儿茶酚基的头孢菌素类的制剂
WO2016100043A1 (en) 2014-12-19 2016-06-23 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
EP3494121B1 (en) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Boron-containing compounds
SG11201908181XA (en) 2017-03-06 2019-10-30 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019118358A1 (en) 2017-12-11 2019-06-20 VenatoRx Pharmaceuticals, Inc. Hepatitis b capsid assembly modulators
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors

Also Published As

Publication number Publication date
RU2654692C2 (ru) 2018-05-22
AU2013355110B2 (en) 2017-11-09
US20150291630A1 (en) 2015-10-15
EP3922635A1 (en) 2021-12-15
CA2893943A1 (en) 2014-06-12
BR112015013123B1 (pt) 2021-02-17
US10214547B2 (en) 2019-02-26
CA2893943C (en) 2021-03-02
HRP20210879T1 (hr) 2021-08-20
US20140171390A1 (en) 2014-06-19
US10669290B2 (en) 2020-06-02
HK1217334A1 (zh) 2017-01-06
EP2928898A4 (en) 2016-06-29
US9422314B2 (en) 2016-08-23
KR102147420B1 (ko) 2020-08-25
US20190225628A1 (en) 2019-07-25
US20180194783A1 (en) 2018-07-12
EP2928898B1 (en) 2021-04-14
JP2018184409A (ja) 2018-11-22
BR112015013123A2 (pt) 2017-07-11
US9828391B2 (en) 2017-11-28
PL2928898T3 (pl) 2021-10-25
AU2013355110A1 (en) 2015-07-02
CN105026407B (zh) 2017-09-08
KR20150109348A (ko) 2015-10-01
RU2015126912A (ru) 2017-01-12
IL239212B (en) 2019-10-31
CN105026407A (zh) 2015-11-04
IL239212A0 (en) 2015-07-30
JP6403219B2 (ja) 2018-10-10
US8912169B2 (en) 2014-12-16
ZA201504200B (en) 2017-09-27
US20250236632A1 (en) 2025-07-24
WO2014089365A1 (en) 2014-06-12
EP2928898A1 (en) 2015-10-14
US20160326189A1 (en) 2016-11-10
JP2016502973A (ja) 2016-02-01
PT2928898T (pt) 2021-07-05

Similar Documents

Publication Publication Date Title
ES2878118T3 (es) Inhibidores de beta-lactamasa
US11414435B2 (en) Beta-lactamase inhibitors
US10294248B2 (en) Beta-lactamase inhibitors
EP3882252B1 (en) Beta-lactamase inhibitors
HK1217334B (en) Beta-lactamase inhibitors